Schnitzer Steel Industries

Yahoo Finance • 10 months ago

16 Companies With The Highest Sustainable Revenue in the US

In this article, we will look into the 16 companies with the highest sustainable revenue in the US. If you want to skip our detailed analysis, you can go directly to the 5 Companies With The Highest Sustainable Revenue in the US. Global G... Full story

Yahoo Finance • 10 months ago

15 Biggest Recycling Companies in America

In this article, we will look into the 15 biggest recycling companies in America. If you want to skip our detailed analysis, you can go directly to the 5 Biggest Recycling Companies in America. Waste Recycling Services Industry: An Analys... Full story

Yahoo Finance • 2 years ago

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”).... Full story

Yahoo Finance • 2 years ago

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the piv... Full story

Yahoo Finance • 2 years ago

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, RFP, USAK

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigation of FSTX, MBCN, RDUS, and ZEN

NEW YORK, July 09, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc (NASDAQ: FSTX) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of FSTX to invoX Pharma for $7.12 per sh... Full story

Yahoo Finance • 2 years ago

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

Radius Health, Inc. RDUS recently announced that the first patient has been randomized in phase II/III study, SCOUT-015, of pipeline candidate, RAD011. SCOUT-015 is a global, randomized, double-blind, placebo-controlled phase II/III study... Full story

Yahoo Finance • 2 years ago

Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

Urges stockholders to vote “FOR” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWI... Full story

Yahoo Finance • 2 years ago

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Advances asset in the neuro-endocrine orphan disease spaceSCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced30+ global sites are planned for the seamless Phase 2/3 pivotal trialPrimary endpoint of h... Full story

Yahoo Finance • 2 years ago

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, TMX, CDEV, MN

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 years ago

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMLP, CTT, RADA, RDUS

NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 3 years ago

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

Transaction delivers immediate value and liquidity to Radius shareholders Result of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at clo... Full story

Yahoo Finance • 3 years ago

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, a... Full story

Yahoo Finance • 3 years ago

Radius Health Expands Non-US Market Footprint for TYMLOS

Globalization has been a key priority for the Company over the past two years Three additional market agreements now signed and executed: - Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries - Pharmbio Korea Inc.... Full story

Yahoo Finance • 3 years ago

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society... Full story

Yahoo Finance • 3 years ago

Radius Files Definitive Proxy and Mails Letter to Stockholders

Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company’s Significant Progres... Full story

Yahoo Finance • 3 years ago

Radius Health Update on Abaloparatide Transdermal System

Company ascertained regulatory clarity for possible forward progression of abalo-TDSAdditional and successful clinical trial would be required to advance towards an NDA filingNew timeline for earliest possible abalo-TDS launch: 2H 2025Base... Full story

Yahoo Finance • 3 years ago

Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has added two new inde... Full story

Yahoo Finance • 3 years ago

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population, and 26.8% vs.... Full story

Yahoo Finance • 3 years ago

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022. The Company will host a con... Full story